Table 5. Summary of previous published case series on PTSS.
| Authors (year of publication) | Sample size | Primary site(s) | SS18 rearrangement | Surgical details | Chemotherapy details | Survival outcome | |
|---|---|---|---|---|---|---|---|
| 1. | Zeren et al [27] (1995) |
25 | Pulmonary | Details NA | Surgery performed = 19 Details NA = 6 |
Details NA | 16% alive with disease; 16% alive without disease at 2–20 years |
| 2. | Essary et al [6] (2001) |
12 | Pleuropulmonary | Positive = 3 | Surgery performed = 11 Details NA = 1 |
ACT = 3 | 2.5-year OS = 58% |
| 3. | Duran-Mendicuti et al [28] (2003) | 5 | Chest wall Pulmonary |
Positive = 4 Untested = 1 |
Surgery = 5 | Details NA | Median OS = 22 months |
| 4. | Okamoto et al [29] (2004) |
11 | Pulmonary | Positive = 11 | Surgery = 10 Details NA = 1 |
Adjuvant chemotherapy = 2 Details NA = 1 |
50% death in 1–9 years |
| 5. | Bégueret et al [9] (2005) | 40 | Intrathoracic | Positive = 39 Details NA = 1 |
Surgery = 33 Details NA = 4 |
Chemotherapy +/- RT = 3 | Median DFS = 43 months |
| 6. | Suster and Moran [30] (2005) | 15 | Mediastinal | Details NA | Surgery = 12 RT = 3 |
Details NA | 80% recurrence at 1–3 years |
| 7. | Hartel et al [31] (2007) | 60 | Positive = 36 | Surgery = 41 Open biopsy = 14 |
Chemotherapy +/- RT = 4 | Median DFS = 17 months | |
| 8. | Galetta et al [8] (2007) | 15 | Pulmonary Mediastinal |
Positive = 15 | Surgery = 15 | ACT = 11 CTRT = 7 RT = 1 |
Median DFS = 15 months |
| 9. | Kim et al [32] (2015) |
14 | Pulmonary | Positive = 6 | Surgery = 8 | Chemotherapy +/- RT = 7 | 2-year DFS 35.7% |
| 10. | Lan et al [26] (2016) |
26 | Pleuropulmonary Mediastinal |
Positive = 26 | Surgery = 20 | ACT = 7 | Median DSS = 14.5 months |
| 11. | Terra et al [33] (2018) | 21 | Mediastinal | Positive = 21 | Surgery = 9 Details NA = 11 |
Chemotherapy +/- RT = 1 | 24% alive with disease at 6–45 months |
| 12. | He et al [12] (2021) |
13 | Pleuropulmonary Mediastinal |
Positive = 13 | Surgery = 10 | Chemotherapy +/- RT = 3 | 5-year OS = 30% |
| 13. | Pieropan et al [24] (2022) | 20 | Pleuropulmonary Mediastinal Chest wall Trachea |
Positive = 17 Tissue not sufficient= 3 |
Surgery = 20 | NACT = 13 ACT = 2 RT = 11 |
5-year OS = 22% Median DFS= 8.5 months Median OS = 25 months |
| 14. | Wang et al [7] (2022) |
132 (12 institutional 121 SEER database) |
Pulmonary | Surgery = 89 | RT = 34 ACT = 8 |
5-year OS = 29% 5-year DSS = 31% |
PTSS: Primary thoracic synovial sarcoma NA: Not available, ACT: Adjuvant chemotherapy, NACT: Neoadjuvant chemotherapy, RT: Radiotherapy, CTRT: Chemoradiotherapy, SEER: Surveillance, Epidemiology and End Results, OS: Overall Survival, DFS: Disease-free survival